Overview
Based in Texas, Mati Therapeutics specializes in pioneering non-invasive drug delivery solutions for ocular diseases. With over a decade of experience in crafting manufacturing equipment, Mati Therapeutics has seamlessly integrated Mecademic’s Meca500—a cutting-edge six-axis robotic arm—into their machinery lineup. The Meca500’s compact size, pinpoint accuracy, EtherCat compatibility, built-in gripper, lack of a separate controller, cost-effectiveness, and rapid delivery time were key factors in its selection. Transitioning from a Contract Manufacturing Organization to establishing an in-house production facility, Mati Therapeutics found the Meca500 instrumental in optimizing space utilization and reducing expenses, ultimately driving up production output and overall company value.
Challenges
Mati Therapeutics, facing pandemic-related delays in manufacturing, shifted to operating their own facility in Bryan, Texas. Challenges included space and time efficiency, especially in the manufacturing process for their punctal plug device. Integration of Meca500 robotic arms addressed these challenges, ensuring precision and quality control. The use of robotic arms significantly streamlined the process, enabling Mati Therapeutics to meet project deadlines effectively while maintaining high standards of product quality.
Automation solution with the Meca500
Automating processes with the Meca500 proved transformative for Mati Therapeutics. The robot’s compact size saved space and costs while ensuring precision critical for medical devices. Integrated control simplified setup and maintenance, enhancing reliability and affordability. Real-time communication optimized coordination and interoperability with other equipment, while built-in gripper systems streamlined setup, reducing errors and disruptions. Quick setup accelerated time to market, boosting competitiveness, and Mati gained control over production, easily adapting to changing demands and ramping up output. By leveraging the Meca500, Mati achieved remarkable efficiency gains, positioning themselves for future growth and success in the industry.
Conclusion
Mati Therapeutics’ transition from relying on a Contract Manufacturing Organization (CMO) to establishing their own manufacturing facility brought significant benefits, with the Meca500 playing a crucial role in their success. This shift provided Mati with greater flexibility, enabling them to adjust production swiftly to meet changing demands and substantially increase their output. Moreover, by taking control of their manufacturing processes, Mati enhanced its value as an acquisition target and partner, positioning itself for future growth and success. Looking ahead, Mati Therapeutics is poised to expand its manufacturing capabilities to serve an international market, reflecting the company’s remarkable journey from adversity to opportunity. This transformative experience underscores the tangible benefits of investing in manufacturing and automation, demonstrating the significant return on investment it can offer for small companies like Mati Therapeutics.
